Prostate biopsy in the diagnosis of prostate cancer: Current trends and techniques

Drugs of Today

Volumn 41, Issue 3, 2005, Pages 179-191

  Lowe, Franklin C ^a,b,c   Nagler, Eli A ^b  

^a Columbia Univ Coll of Phys/Surgs ^*  (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; LEVOFLOXACIN; LIDOCAINE; PROSTATE SPECIFIC ANTIGEN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TINIDAZOLE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; CANCER SCREENING; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOCAL ANESTHESIA; MALE; MORTALITY; NEEDLE; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; URINARY TRACT INFECTION;

EID: 18244386977     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.3.892523     Document Type: Review

References (87)

1. Oesterling, J.E., Jacobsen, S.J., Chute, G.G. et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993, 270: 860-4.
2. Lowe, F.C., Cavallo, C.B., Kahane, H. Epidemiological evidence suggesting a PSA cut-point of 2.5 ng/ml for intiating a prostate biopsy: A review of 36,316 patients with biopsy and PSA data. J Urol 2003, 169 (Suppl.): 341.
3. Smith, D.S., Carvalhal, G.F., Mager, D.E., Bulock, A.D., Catalona, W.J. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol 1998, 160: 1734-8.
4. Matlaga, B.R., Eskew, LA., McCullough, D.L. Prostate biopsy: Indications and technique. J Urol 2003, 169: 12-9.
5. Cooner, W.H. Ultrasound in prostatic cancer. JAMA 1988, 259: 1015.
6. Applewhite, J.C., Matlaga, B.R., McCullough, D.L., Hall, M.C. Transrectal ultrasound and biopsy in the early detection of prostate cancer. Cancer Control 2001, 8: 141-50.
7. Hodge, K.K., McNeal, J.E., Terris, M.K., Stamey, T.A. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989, 142: 71-5.
8. Ochiai, A., Babaian, R.J. Update on prostate biopsy technique. Curr Opin Urol 2004, 14: 157-62.
9. Lowe, F.C., Gilbert, S.M., Kahane, H. Evidence of increased prostate cancer detection in men aged 50 to 59: A review of 324,684 biopsies performed between 1995 and 2002. Urology 2003, 62: 1045-9.
10. American Cancer Society. Prostate Cancer Statistics 2003. Available at: http://www.cancer.org/docroot/STT/stt_0.asp.
11. Gilbertson, V.A. Cancer of the prostate gland: Results of early diagnosis and therapy undertaken for cure of the disease. JAMA 1971, 215: 81-4.
12. Kozlowski, J.M., Grayhack, JT. Carcinoma of the prostate. In: Adult and Pediatrie Urology, 4th Ed. Gillenwater, J.Y., Grayhack, J.T., Howard, S.S. et al. (Eds.). Lippincott, Williams and Wilkins, Philadelphia 2002, Vol 2, pp. 1472-73.
13. Hsieh, K., Albertsen, P.C. Populations at high risk for prostate cancer. Urol Clin North Am 2003, 30: 669-76.
14. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Databases: Incidence - SEER 11 Regs + AK Public-Use, Nov 2003 Sub for Expanded Races (1992-2001) and Incidence - SEER 11 Regs Public-Use, Nov 2003 Sub for Hispanics (1992-2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004, based on the November 2003 submission.
15. Freeman, V.L., Durazo-Arvizu, R., LaShon, C. et al. Racial differences in survival among men with prostate cancer and comorbidity at time of diagnosis. Am J Public Health 2004, 94: 803-8.
16. Bruner, D.W., Moore, D., Parlanti, A., Dorgan, J., Engstrom, P. Relative risk of prostate cancer for men with affected relatives: Systematic review and meta-analysis. Int J Cancer 2003, 107: 797-803.
17. Eldon, B.J., Jonsson, E., Tomasson, J., Tryggvadottir, L., Tulinius, H. Familial risk of prostate cancer in Iceland. BJU Int 2003, 92: 915-9.
18. Schroder, RH., van der Cruijsen-Koeter, I., de Koning, H.J., Vis, A.N., Hoedemaeker, R.F., Kranse, R. Prostate cancer detection at low prostate specific antigen. J Urol 2000, 163: 806-12.
19. Freedland, S.J., Mangold, L.A., Epstein, J.I., Partin, A.W. Biopsy indication-a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/ml or less and T1c disease. Urology 2004, 63: 887-91.
20. Iqbal, N., Bhatti, A.N., Husain, S. Role of digital rectal examination and prostate specific antigen in detecting carcinoma prostate. J Coll Physicians Surg Pak 2003, 13: 340-2.
21. Catalona, W.J., Smith, D.S., Ratliff, T.L. et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991, 324: 1156-61.
22. Tsui, K.H., Chang, P.L., Wang, T.M., Hsieh, M.L. Diagnosis of prostate cancer: Comparison of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. Changgeng Yi Xue Za Zhi 1997, 20: 23-8.
23. Crawford, E.D., DeAntoni, E.P., Etzioni, R., Schaefer, V.C., Olson, R.M., Ross, C.A. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology 1996, 47:863-9.
24. Crawford, E.D. Prostate Cancer Awareness Week: September 22 to 28, 1997. CA Cancer J Clin 1997, 47: 288-96.
25. Slovacek, K.J., Riggs, M.W., Spiekerman, A.M., Speights, V.O. Jr. Use of age-specific normal ranges for serum prostate-specific antigen. Arch Pathol Lab Med 1998, 122: 330-2.
26. Punglia, R.S., D'Amico, A.V., Catalona, W.J., Roehl, K.A., Kuntz, K.M. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003, 349: 335-42.
27. Reissigl, A., Klocker, H., Pointner, J. et al. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening. Urology 1996, 48 (6A Suppl): 62-6.
28. Catalona, W.J., Partin, A.W., Slawin, K.M. et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998, 279: 1542-7.
29. Partin, A.W., Brawer, M.K., Subong, E.N. et al. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis 1998, 1: 197-203.
30. Chen, Y.T., Luderer, A.A., Thiel, R.P., Carlson, G., Cuny, C.L., Soriano, T.F. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 1997, 50: 655-6.
31. Carter, H.B., Pearson, J.D., Metter, E.J. et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992, 267: 2215-20.
32. Seaman, E., Whang, M., Olsson, C.A., Katz, A., Cooner, W.H., Benson, M.C. PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am 1993, 20: 653-63.
33. Ohori, M., Dunn, J.K., Scardino, P.T. Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Urology 1995, 46: 666-71.
34. Lujan, M., Paez, A., Lianes, L., Miravalles, E., Berenguer, A. Prostate specific antigen density. Is there a role for this parameter when screening for prostate cancer? Prostate Cancer Prostatic Dis 2001, 4: 146-9.
35. Catalona, W.J., Richie, J.P., deKernion, J.B. et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: Receiver operating characteristic curves. J Urol 1994, 152: 2031-6.
36. Watanabe, H., Igari, D., Tanahasi, Y, Harada, K., Saito, M. Development and application of new equipment for transrectal ultrasonography. J Clin Ultrasound 1974, 2: 91-8.
37. Carter, H.B., Hamper, U.M., Sheth, S., Sanders, R.C., Epstein, J.I., Walsh, P.C. Evaluation of transrectal ultrasound in the early detection of prostate cancer. J Urol 1989, 142: 1008-10.
38. Sedelaar, J.P., Vijverberg, P.L., De Reijke, T.M. et al. Transrectal ultrasound in the diagnosis of prostate cancer: State of the art and perspectives. Eur Urol 2001, 40: 275-84.
39. Nash, A.N., Bruce, J.S., Indudhara, R., Shinohara, K. Transrectal ultrasound guided prostatic nerve blockade eases systematic needle biopsy of the prostate. J Urol 1996, 155: 607-9.
40. Soloway, M.S. Editorial response to Nitrous oxide vs periprostatic nerve block with 1% lidocaine during transrectal ultrasound guided biopsy of the prostate: A prospective, randomized, controlled trial. J Urol 2003, 170: 1883.
41. Alavi, A.S., Soloway, M.S., Vaidya, A., Lynne, C.M., Gheiler, E.L. Local anesthesia for ultrasound guided prostate biopsy: A prospective randomized trial comparing 2 methods. J Urol 2001, 166: 1343-5.
42. Stirling, B.N., Shockley, K.F., Carothers, G.G., Maatman, T.J. Comparison of local anesthesia techniques during transrectal ultrasound-guided biopsies. Urology 2002, 60: 89-92.
43. Lynn, N.N., Collins, G.N., Brown, S.C., O'Reilly, P.H. Periprostatic nerve block gives better analgesia for prostatic biopsy. J Urol 2003, 169: 1606-7.
44. Soloway, M.S., Obek, C. Periprostatic local anesthesia before ultrasound guided prostate biopsy. J Urol 2000, 163: 172-3.
45. Ozden, E., Yaman, O., Gogus, C., Ozgencil, E., Soygur, T. The optimum doses of and injection locations for periprostatic nerve blockade for transrectal ultrasound guided biopsy of the prostate: a prospective, randomized, placebo controlled study. J Urol 2003, 170: 2319-22.
46. Villers, A., Mouton, D., Rebillard, X. et al. Biopsy technique and biopsy schemes for a first series of prostatic biopsies. Prog Urol 2004, 14: 144-53.
47. Carey, J.M., Korman, H.J. Transrectal ultrasound guided biopsy of the prostate. Do enemas decrease clinically significant complications? J Urol 2001, 166: 82-5.
48. Shandera, K.C., Thibault, G.P., Deshon, G.E. Jr. Variability in patient preparation for prostate biopsy among American urologists. Urology 1998, 52: 644-6.
49. Aron, M., Rajeev, T.P., Gupta, N.P. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: A randomized controlled study. BJU Int 2000, 85: 682-5.
50. Sabbagh, R., McCormack, M., Peloquin, F. et al. A prospective randomized trial of 1-day versus 3-day antibiotic prophylaxis for transrectal ultrasound guided prostate biopsy. Can J Urol 2004, 11: 2216-9.
51. Cookson, M.S. Update on transrectal ultrasound-guided needle biopsy of the prostate. Mol Urol 2000, 4: 93-7; discussion 99.
52. Levine, M.A., Ittman, M., Melamed, J., Lepor, H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 1998, 159: 471-6.
53. Rabets, J.C., Jones, J.S., Patel, A., Zippe, C.D. Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol 2004, 172: 94-7.
54. Rabbani, R, Stroumbakis, N., Kava, B.R., Cookson, M.S., Fair, W.R. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998, 159: 1247-50.
55. Eskew, L.A., Bare, R.L., McCullough, D.L. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997, 157: 199-203.
56. Presti, J.C., Chang, J.J., Bhargava, V. Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000, 163: 163-7.
57. Babaian, R.J., Toi, A., Kamoi, K. et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000, 163: 152-7.
58. Chrouser, K.L., Lieber, M.M. Extended and saturation needle biopsy for the diagnosis of prostate cancer. Curr Urol Rep 2004, 5: 226-30.
59. M D, P.M., Niemann, T.H., Bahnson, R.R. Extended sector biopsy for detection of carcinoma of the prostate. Urol Oncol 2001, 6: 91-3.
60. de la Taille, A., Antiphon, P., Salomon, L. et al. Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology 2003, 61: 1181-6.
61. Yamamoto, S., Ito, T., Aizawa, T. et al. Does transrectal ultrasound guided eight-core prostate biopsy improve cancer detection rates in patients with prostate-specific antigen levels of 4.1-10 ng/mL? Int J Urol 2004, 11: 386-91.
62. Presti, J.C. Jr., O'Dowd, G.J., Miller, M.C., Mattu, R., Veltri, R.W. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol 2003, 169: 125-9.
63. Paul, R., Scholer, S., van Randenborgh, H. et al. Morbidity of prostatic biopsy for different biopsy strategies: Is there a relation to core number and sampling region? Eur Urol 2004, 45: 450-5.
64. Helpap, B.C., Bostwick, D.G., Montironi, R. The significance of atypical adenomatous hyperplasia and prostatic intraepithelial neoplasia for the development of prostate carcinoma. An update. Virchows Arch 1995, 426: 425-34.
65. Lefkowitz, G.K., Sidhu, G.S., Torre, P., Lepor, H., Taneja, S.S. Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling? Urology 2001, 58: 999-1003.
66. Park, S., Shinohara, K., Grossfeld, G.D., Carroll, P.R. Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy. J Urol 2001, 165: 1409-14.
67. Ouyang, R.C., Kenwright, D.N., Nacey, J.N., Delahunt, B. The presence of atypical small acinar proliferation in prostate needle biopsy is predictive of carcinoma on subsequent biopsy. BJU Int 2001, 87: 70-4.
68. Alsikafi, N.R, Brendler, C.B., Gerber, G.S., Yang, X.J. High-grade prostatic intraepithelial neoplasia with adjacent atypia is associated with a higher incidence of cancer on subsequent needle biopsy than high-grade prostatic intraepithelial neoplasia alone. Urology 2001, 57: 296-300.
69. Iczkowski, K.A., Bostwick, D.G. Prostate biopsy interpretation. Current concepts, 1999. Urol Clin North Am 1999, 26: 435-52.
70. Borboroglu, P.G., Comer, S.W., Riffenburgh, R.H., Amling, C.L. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol 2000, 163: 158-62.
71. Rodriguez-Patron Rodriguez, R., Mayayo, D.T., Gonzalez, G.A., Zuccarino, A.L., Garcia, G.R., Cuesta, R.C. Can indexes based on PSA determine which patients should undergo repeated ultrasound-guided transrectal prostatic biopsy? Study on 546 patients who underwent repeated biopsy. Arch Esp Urol 2002, 55: 225-34.
72. Busby, J.E., Evans, C.P. Determining variables for repeat prostate biopsy. Prostate Cancer Prostatic Dis 2004, 7: 93-8.
73. Chon, C.H., Lai, F.C., McNeal, J.E., Presti, J.C. Jr. Use of extended systematic sampling in patients with a prior negative prostate needle biopsy. J Urol 2002, 167: 2457-60.
74. Stewart, C.S., Leibovich, B.C., Weaver, A.L., Lieber, M.M. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001, 166: 86-92.
75. Patel, A.R., Jones, J.S., Rabets, J., DeOreo, G., Zippe, C.D. Parasagittal biopsies add minimal information in repeat saturation biopsies. Urology 2004, 63: 87-9.
76. Lowe, RC., Cavallo, C.B., Kahane, H. Changing patterns of prostate biopsy techniques from 1997 to 2002: A review of 233,989 biopsies. J Urol 2003, 169 (Suppl): 433-4.
77. Gupta, C., Ren, J.Z., Wojno, K.J. Individual submission and embedding of prostate biopsies decreases rates of equivocal pathology reports. Urology 2004, 63: 83-6.
78. Gottfried, H.W., Volkmer, B. Complications of transrectal prostate biopsy. Determination of current status. Urologe A 2003, 42: 1022-8.
79. Strate, L.L., O'Leary, M.P., Carr-Locke, D.L. Endoscopic treatment of massive rectal bleeding following prostate needle biopsy. Endoscopy 2001, 33: 981-4.
80. Raaijmakers, R., Kirkels, W.J., Roobol, M.J., Wildhagen, M.F., Schrder, F.H. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002, 60: 826-30.
81. Rietbergen, J.B., Kruger, A.E., Kranse, R., Schroder, F.H. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology 1997, 49: 875-80.
82. Rodriguez, L.V., Terris, M.K. Risks and complications of transrectal ultrasound guided prostate needle biopsy: A prospective study and review of the literature. J Urol 1998, 160: 2115-20.
83. Emiliozzi, P., Corsetti, A., Tassi, B., Federico, G., Martini, M., Pansadoro, V. Best approach for prostate cancer detection: A prospective study on transperineal versus transrectal six-core prostate biopsy. Urology 2003, 61: 961-6.
84. Shinghal, R., Terris, M.K. Limitations of transperineal ultrasound-guided prostate biopsies. Urology 1999, 54: 706-8.
85. Niesel, T., Breul, J., Hartung, R. Diagnostic value of additional systematic prostate biopsies in patients undergoing transurethral resection of the prostate. Urology 1997, 49: 869-73.
86. Zigeuner, R., Schips, L., Lipsky, K. et al. Detection of prostate cancer by TURP or open surgery in patients with previously negative transrectal prostate biopsies. Urology 2003, 62: 883-7.
87. Shinohara, K., Gulati, M., Koppie, T.M., Terris, M.K. Transperineal prostate biopsy after abdominoperineal resection. J Urol 2003, 169: 141-4.